top of page

Neurvati Neurosciences is a Blackstone owned development company that focuses on late stage assets in neuroscience - the first project targets an NMDA subunit, called NR2B, for GRIN disorders

  • Dec 9, 2024
  • 1 min read

CEO Bruce Leuchter, a physician trained in neurology and psychiatry himself, describes the rational and structure behind Neurvati, and how they are looking for opportunities with proof of concept data. Plus, the unmet need in GRIN disorders and why GRIN Therapeutics is targeting it through NMDA.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page